M&As this week: Epigenomics, C R Bard, Malosa Medical

27 April 2017 (Last Updated April 27th, 2017 18:30)

Molecular diagnostics company Epigenomics has entered a business combination agreement (BCA) with Cathay Fortune International (CFIC) regarding the takeover of Epigenomics by CFIC’s subsidiary, Blitz F16-83 GmbH.

Molecular diagnostics company Epigenomics has entered a business combination agreement (BCA) with Cathay Fortune International (CFIC) regarding the takeover of Epigenomics by CFIC’s subsidiary, Blitz F16-83 GmbH.

Blitz F16-83 will be named Summit Hero Holding GmbH, and is to acquire all outstanding ordinary shares of Epigenomics by paying €7.52 ($8.19) of an ordinary share in cash. The transaction values Epigenomics’ equity at approximately €171m ($186.23m), including net cash.

The acquisition is expected to be close midway through the year, enabling Epigenomics to have sufficient capital resources to commercialise its products worldwide and expand its research and development (R&D) activities related to its unique cancer biomarker technology. 

"The acquisition will enable Epigenomics to have sufficient capital resources to commercialise its products worldwide and expand its R&D activities."

American company Becton, Dickinson and Company (BD), intends to buy C R Bard Inc for a purchase consideration of $24bn or $317 per Bard’s common share in cash and stock.

The target company’s shareholder will receive approximately $222.93 in cash and 0.5077 shares of BD stock of a Bard share or a total of $317 of a Bard common share.

The transaction is due to close towards the end of the year. It will allow BD to expand its portfolio of clinically relevant products and to increase its opportunities in growing clinical areas such as peripheral vascular therapy, oncology and biosurgery. 

Surgical devices provider Beaver-Visitec International has completed the acquisition of Malosa Medical, an ophthalmologic surgical instruments supplier based in Halifax, UK.

The acquisition enables Beaver-Visitec International to expand and advance its leading single-use surgical product portfolio.